| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Loss from operations | -628,145 | - | -758,618 | -1,085,257 |
| Research and development subsidy | 415 | - | - | - |
| Interest income | 294 | - | 1,074 | - |
| Interest expense, nonoperating | - | - | - | 34,114 |
| Interest expense | 24,046 | - | 28,028 | - |
| Investment income, interest | - | - | - | 1,460 |
| Income tax expense | - | 0 | - | - |
| Net other (expense) income | -23,337 | - | -26,954 | - |
| Loss before income taxes | -651,482 | -528,367 | -785,572 | -1,117,911 |
| Net loss | -651,482 | -528,367 | -785,572 | -1,117,911 |
| Other comprehensive income - foreign currency translation adjustment | 57,335 | 20,263 | 7,516 | 137,638 |
| Comprehensive loss | -594,147 | -508,104 | -778,056 | -980,273 |
| Loss per share basic (in dollars per share) | -0.17 | -0.16 | -0.24 | -0.06 |
| Loss per share diluted (in dollars per share) | -0.17 | -0.16 | -0.24 | -0.06 |
| Weighted average shares outstanding (in shares) | 3,874,085 | 3,262,002 | 3,261,911 | 17,306,689 |
CHINA PHARMA HOLDINGS, INC. (CPHI)
CHINA PHARMA HOLDINGS, INC. (CPHI)